A Study of Adalimumab in Japanese Subjects with Moderately to Severely Active Ulcerative Colitis.

A Multi-Center, Randomized, Double-Blind, Placebo-controlled Study of Adalimumab in Japanese Subjects with Moderately to Severely Active Ulcerative Colitis.

Status

Unknown

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080220693

Enrollment

255

Registered

2009-03-12

Start date

2009-03-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative colitis

Interventions

investigational material(s) Generic name etc : adalimumab INN of investigational material : adalimumab Therapeutic category code : 399 Agents affecting metabolism, n.e.c. Dosage and Administration for

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Moderately to severely active UC.

Exclusion criteria

Exclusion criteria: Crohn's disease History of TB Pregnant women

Design outcomes

Primary

Measure	Time frame
Mayo score at Week 8 and Week 52	—

Secondary

Measure	Time frame
Mayo score at Week 32 IBDQ Adverse events	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026